Pain is the most common manifestation of both acute and chronic inflammation that affects patients with rheumatic disease. There is a complex interplay of interactions between cytokines, mediators of inflammation, and ion channels that influence the final immune response and our perception of pain. Endocannabinoids, a group of endogenous bioactive lipids, have important immunomodulatory effects that can influence both inflammation and pain.
The primary components of the endocannabinoid signaling system (CB1, CB2, and FAAH) are characteristically expressed in the joints of both osteoarthritic (OA) and rheumatoid arthritic (RA) patients, with compelling evidence to demonstrate an active participation in the pathophysiology of joint pain. Preclinical and clinical studies support the therapeutic application of cannabinoids in the treatment of chronic pain. Patients suffering from chronic arthritic and musculoskeletal pain may experience pain relief from medicinal cannabis.
Use of Medical Cannabis is legal in the State of New York. If your physician determines that medical cannabis is an appropriate treatment for you and is registered with the New York State Department of Health’s Medical Marijuana Program, you may be eligible for certification.
Our practice is approved by the State of New York to issue Medical Cannabis patient certification for the approved indications.